EGFR and non-small cell lung carcinoma: In VerStrat Good group of NSCLC patients with wild-type or unknown status EGFR, the OS was not different between the patients treated with chemotherapy and those treated with erlotinib (10.9 versus 11.0 months; HR, 1.06; 95% CI, 0.77–1.46; P = 0.714), suggesting that EGFR-TKIs could be a rational choice for this subpopulation in second-line setting.